Chemring manufactures flares and decoy measures to deter missile attacks on aircraft A British defence company that supplies the Royal Air Force has received a £1bn takeover approach from a private equity firm. Chemring (CHG.L), which supplies countermeasures for Typhoon and F-35 jets, has reportedly received and rejected an offer from Boston-based Bain Capital in the past few weeks. The US company offered 390p per share, according to Sky News. That is only 32p more than what the FTSE 250 (^FTMC) company’s shares were changing hands for on Friday. Bain is said to be preparing a second offer. A spokesman for Chemring, which has not confirmed or denied the approach to shareholders, declined to comment on “speculation”. The company will hold its annual shareholder meeting later this week. Shares jumped 8.7pc higher on Monday to 389p – just below the reported level of the takeover. The prospect of a US takeover may raise national security concerns at a time when the UK is under pressure to bolster its independent defence capabilities. Trump administration officials have in recent weeks signalled European allies can no longer rely on the US for military protection, prompting panic across the continent. The approach would make Chemring the latest British company to be circled by private equity suitors, at a time when overseas investors view domestic companies as “cheap”. Both Britvic and Royal Mail’s owner were recently taken private via takeovers last year. Chemring specialises in making flares, decoys and “chaff”, small pieces of metal or glass fibre dispersed to confuse radar and incoming missiles. The devices are used by RAF aircraft and many of those operated by the US and other Nato countries. Its sensors and information division also provides electronic warfare software used to jam communications and devices for detecting chemical and biological hazards. Like other defence companies, analysts have said it should be well-positioned to benefit from an expected surge in defence spending around the world amid rising geopolitical tensions. The war in Ukraine has already spurred a wave of rearmament across the West, with the company’s order book getting a boost from the large number of US-made F-35 jets being bought by allies including Britain, Australia and Germany. Chemring is also set to benefit from American orders for the F-35, with the US Department of Defense preparing to buy more than 2,000 of the jets through to 2044. Countermeasures and energetics remains the largest part of Chemring’s business by far, bringing in around 60pc or £300m of its annual sales. In 2024, it racked up £523m of orders, taking its pipeline to £933m. While the Stoxx index for European defence companies has surged 32pc over the past year, Chemring’s shares had barely moved before news of the approach from Bain emerged. View Comments
FTSE-listed RAF supplier becomes target of £1bn US takeover
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...